Progress of targeted immunotherapy in treatment of relapsed/refractory follicular lymphoma
10.3760/cma.j.issn.1009-9921.2019.02.003
- VernacularTitle:复发难治滤泡淋巴瘤靶向免疫治疗进展
- Author:
Zhijuan LIN
1
;
Zhifeng LI
;
Bing XU
Author Information
1. 厦门大学附属第一医院血液科 361003
- Keywords:
Lymphoma,follicular;
Immunotherapy;
Molecular targeted therapy
- From:
Journal of Leukemia & Lymphoma
2019;28(2):72-74
- CountryChina
- Language:Chinese
-
Abstract:
Follicular lymphoma (FL) is the most common indolent B-cell non-Hodgkin lymphoma. The overall survival of FL is near 15 years. However, the survival would be significantly shortened in refractory, early-relapsed or transformed setting. The 60th American Society of Hematology (ASH) Annual Meeting reported several latest and optimal approaches to relapsed/refractory FL, with a focus on immune-based therapies and target agents for FL. This paper reviews and makes comments about these clinical trials.
